Renee N Donahue

May 10, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-46961-x, published online 27 March 2024The original version of the article file contained some inaccuracies in the main text. To avoid misinterpretation of the findings, the following corrections have now been made in the revised PDF and HTML versions of the article file. Abstract.

Mar 26, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

AbstractChemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint).